• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 25, 2014

View Archived Issues

BARDA embraces products developed to treat the public and terrorism

Biomedical Advanced Research and Development Authority (BARDA), which evolved out of the biodefense-focused Project BioShield, has moved beyond simply funding drugs and devices that might be used in the event of terrorism. Read More

Booze dues: Aldea gets $24M in series B round for anti-alcohol therapy

With $24 million in series B financing, Aldea Pharmaceuticals Inc. will gather more safety data this year and in the second half of 2015 start a phase II trial in acute alcohol intoxication with its lead candidate, AD-6626, based on technology licensed from Stanford University. Read More

Industry veteran Yu helping to build China's biotech future

SHANGHAI – Innovent Biologics Inc. and its staff of 170 took occupancy of its $140 million facility in Suzhou's Biobay Industrial Park this month. The impressive facility designed with ancient fengshui principles in mind, houses two state-of-the-art 1,000-liter bioreactors. Read More

Deep sequencing reveals mosaic mutations in brain disorders

Using deep sequencing of candidate genes, researchers have identified mosaic mutations – mutations that exist in only some of the body's cells, because they arose as a result of a copying error during cell division rather than being present in the sperm or egg – in about a third of patients with malformations of the cerebral cortex. Read More

Zai has arrived; inks deal with Sanofi for preclinical COPD drugs

SHANGHAI – Newly minted Zai Lab Ltd., of Shanghai, has made its eagerly awaited debut announcement, obtaining global rights to two Sanofi SA preclinical compounds for chronic respiratory diseases. Read More

Huya widens net, links up with CZCBD for drug candidates

SHANGHAI – Privately held Huya Bioscience International, of San Diego, has signed a strategic partnership with the Changzhou Center for Biotech Development (CZCBD) for the advancement of innovative drug and biomarker candidates. Read More

Financings

Bioniche Life Sciences Inc., of Belleville, Ontario, said it filed a preliminary short form prospectus with securities regulatory authorities in each of the provinces in Canada, excluding Quebec, in connection with an overnight marketed offering with Dundee Securities Ltd. acting as the sole agent. The offering will consist of units, with the price per unit to be determined in the context of the market. Read More

Other news to note

Sucampo Pharmaceuticals Inc., of Bethesda, Md., said its subsidiary, Sucampo AG, revised its exclusive global manufacturing and supply agreement with its manufacturing and development partner, R-Tech Ueno Ltd., of Tokyo, for clinical and commercial supplies of Amitiza (lubiprostone) in most global markets. Read More

In the clinic

Aastrom Biosciences Inc., of Ann Arbor, Mich., said results from an open-label phase IIa study of ixmyelocel-T, its cell therapy for treating advanced heart failure due to ischemic dilated cardiomyopathy (DCM), were published in Circulation Research. Read More

Stock movers

Read More

Appointments and advancements

Galena Biopharma Inc., of Portland, Ore., named Mark W. Schwartz president and CEO. Read More

Bench Press: BioWorld looks at translational medicine

Despite the fact that the Ebola virus has hijacked the headlines, many other infectious agents remain concerns for the World Health Organization and others who deal with emerging pathogens full-time. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe